Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE Following the finding that the p16 antitumor peptide dramatically inhibits the growth of aggressive leukemia/lymphoma through the restoration of p16 function using the Wr-T peptide transporter system, in this study, we developed a systemic therapy using mouse‑p16 peptide (m‑p16) in subcutaneous p16‑null mouse bladder tumors. 23292502 2013
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE Methylation of DAPK and p16(INK4a) genes is a frequent event in this lymphoma at its initial presentation, but may not be associated with tumor progression. 18820662 2008
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 GeneticVariation disease BEFREE Fluorescent in situ hybridization (FISH) analysis was performed to confirm CGH array data and to detect lymphoma-associated gene rearrangements. p14(ARF)/p16(INK4a) CDKN2A gene quantification, methylation analysis, and immunohistochemical detection were also performed. 18311490 2008
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE Further studies are needed to determine whether p16 is widely suppressed in immunosuppression-induced lymphoma. 17052484 2006
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 PosttranslationalModification disease BEFREE Seven of seven PCLBCL, leg type, patients with deletion of 9p21.3 and/or complete methylation of CDKN2A died as a result of their lymphoma. 16330669 2006
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 AlteredExpression disease BEFREE Our observation of frequent p14 gene abnormalities (90%) and inactivation (40-60%) was in striking contrast to the same pathological subtype of systemic lymphoma in which p14 gene abnormalities and inactivation were infrequent, suggesting a difference in carcinogenesis between PCNSL and systemic lymphoma. 15649253 2005
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE In addition, homozygous deletions of p15, p16 and p14 genes in 5 out of 31 samples were detected; 3 were from nasal NK cell lymphoma and 2 from blastic NK cell lymphoma / leukemia. 11676855 2001
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 GeneticVariation disease BEFREE Thus, unlike the p16 and p15 tumor suppressor genes, which are frequently deleted and inactivated in brain lymphoma and represent a striking contrast to systemic lymphoma, MMAC1 may not play an important role in carcinogenesis in this tumor, as in the systemic counterpart. 11908870 2001
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE Loss of INK4a/alternate reading frame (ARF) in mice is associated with increased incidence of other tumors such as lymphoma and fibrosarcoma. 11719444 2001
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE The two patients with p16 loss both died of lymphoma, whereas the two patients with normal p16 expression are alive. 10976700 2000
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 AlteredExpression disease BEFREE Furthermore, low E2F-1 expression and p16INK4A inactivation may serve as prognostic markers for patients with this type of lymphoma. 10803523 2000
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 GeneticVariation disease BEFREE In addition, a large variation in the methylation patterns of p16 exon 1 was observed, not only from one lymphoma to another, but also within a given tumor. 10477703 1999
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE In this study, we have used YAC probes encompassing the CDKN2 locus to analyze by fluorescence in situ hybridization patients with leukemia and lymphoma and translocations involving 9p in order to establish the CDKN2 status in relation to the karyotype. 9258663 1997
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 GeneticVariation disease BEFREE To determine if p19 genetic alterations play a role in hematopoietic malignancies, we examined DNA from 45 childhood newly diagnosed acute lymphocytic leukemias (ALLs), 30 acute myeloblastic leukemias (AMLs), 10 chronic myelocytic leukemias (CMLs), 45 adult T cell leukemias (ATLs), 70 non-Hodgkin's lymphomas (NHLs), and 20 multiple myelomas (MM) as well as 14 ALL, 20 AML, two ATL, and five lymphoma cell lines. 8946928 1996
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE Role of the cyclin-dependent kinase 4 and 6 inhibitor gene family p15, p16, p18 and p19 in leukemia and lymphoma. 9031081 1996
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE We have determined the incidence of structural abnormalities affecting CDKN2 by DNA blot in a panel of 231 cases of leukemia and lymphoma and 66 cell lines derived from patients with lymphoid malignancies with defined cytogenetic abnormalities. 7849311 1995
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE The transcription of the mts1 gene putatively involved in the control of tumor metastasis was studied in three human lymphoma cell lines: MOLT-4, CEM and Jurkat. 7536040 1995